ReviewPrzeglad gastroenterologiczny2026
Personalised therapy in pancreatic carcinoma - a forthcoming opportunity?
Review in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer remains the leading cause of cancer-related mortality. Despite overall advancements in oncological treatment, therapeutic approach remains limited, especially for advanced disease. Precision medicine, basing on the patient's unique characteristics, including environment, lifestyle, genetics, and disease profile, may complete the cancer management. Starting from the current therapeutic algorithms, this review explores the potential role of personalised treatment as a key to improve the outcomes. Molecular classification based on identification of genetic mutations aids better therapy selection in view of the disease heterogeneity. Patient-derived organoids help in adjusting the current treatment standards to specific tumours, assessing the potential treatment efficacy before the introduction of therapy, whereas the mRNA vaccines, as the novel adjuvant approach, may support the achievement of long-term survival. The proposed opportunities could facilitate the treatment strategies, and continued research is essential for improving patient survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.